Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to six international sites that are expected to open, where subjects are being tested with QRX003 as monotherapy. Combined data from Studies CL-QRX003-002 and CL-QRX003-003 is anticipated to provide QRX003 with the b ...

Exhibit 99.1 ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical- stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the quarter ended March 31, 2025. Quoin CEO Dr. Michael Myers said, "The first quarter of 2025 has seen continued momentum across all aspects of our business. We repor ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-37846 QUOIN PHARMACEUTICALS LTD. (Exact name of registrant as specified in its charter) ...

Core Insights - Quoin Pharmaceuticals has released the second episode of its "Living with Netherton" video series, featuring a 79-year-old patient, Norma Coles, who has lived with Netherton Syndrome for decades, highlighting the need for awareness and treatment [1][2][4] - The company aims to raise awareness and improve education regarding Netherton Syndrome, which currently has no FDA-approved treatment, emphasizing the urgency for effective therapeutic options [2][5] Company Overview - Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [1][7] - The company is committed to addressing unmet medical needs and has a pipeline that includes four products targeting various rare conditions, including Netherton Syndrome [7] Product Development - Quoin's lead product candidate, QRX003, is currently undergoing evaluation in four clinical trials for the treatment of Netherton Syndrome, with initial data showing improvements in skin healing and quality of life [5][6] - QRX003 is a topical lotion designed to normalize skin-shedding processes and strengthen the skin barrier, addressing the underlying issues of Netherton Syndrome [6] Campaign and Advocacy - The NETHERTON NOW campaign is central to Quoin's efforts to raise awareness and support for individuals affected by Netherton Syndrome, sharing real patient experiences to foster understanding [4][5] - The company emphasizes the importance of patient stories, like that of Norma Coles, to illustrate the challenges faced by those living with this rare genetic disorder [2][5]

Episode Highlights a Truly Remarkable Patient Story Spanning 79 Years Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company's NETHERTON NOW website ASHBURN, Va., April 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare ...

Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks TreatmentHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary MedicationsWith Patient's Pruritus Almost Completely Eliminated, Patient Continues to Experience Zero Nightly Sleep Disturbance No Adverse Events Reported from 6 Weeks of Whole Body Treatment with QRX003Approval Received to Initiate Whole Body Testing of a Second Pediatric Patient ASHBURN, Va., ...

Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks TreatmentHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary MedicationsWith Patient’s Pruritus Almost Completely Eliminated, Patient Continues to Experience Zero Nightly Sleep Disturbance No Adverse Events Reported from 6 Weeks of Whole Body Treatment with QRX003Approval Received to Initiate Whole Body Testing of a Second Pediatric Patient ASHBURN, Va., ...

Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic DermatitisThird Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for Netherton Syndrome Until 2045 ASHBURN, Va., March 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late-stage clinical, specialty pharmaceutical company focused on the development and commercialization of therapeutic prod ...

Financial Performance and Position - The company has incurred net losses every year since inception, with an accumulated deficit of approximately $55.2 million as of December 31, 2024[132]. - Cash balances totaled $3.6 million and investments were $10.4 million as of December 31, 2024, indicating limited cash available for operations[132]. - Significant expenses and increasing operating losses are anticipated for the foreseeable future, with no revenue generated from product sales to date[135]. - Future profitability is uncertain and depends on successful completion of clinical trials and obtaining necessary regulatory approvals[142]. - The company may need to raise additional capital to support operations, which may not be available on acceptable terms[140]. - The company expects significant additional capital will be needed in the future, which may result in substantial dilution for existing shareholders if equity securities are issued[261]. Product Development and Regulatory Challenges - The company does not expect to generate revenue from product sales until successful development and marketing approval of product candidates, which may take several years[133]. - The success of product candidates is contingent on various factors, including successful clinical trial outcomes and regulatory approvals[145]. - The company is currently facing significant challenges in completing preclinical and clinical development, which could lead to increased costs and hinder revenue generation from product sales[153]. - Clinical trials may reveal severe side effects that could delay or prevent regulatory approval, impacting market acceptance and commercialization costs[154]. - The company cannot predict the timing of revenue from future products until regulatory approval is obtained, which may be subject to various delays and complications[157]. - Regulatory authorities may impose restrictions on product distribution, require additional studies, or even withdraw approvals, which could adversely affect the company's financial condition[162]. - The company intends to apply for orphan drug designation for QRX003, but success is uncertain and does not guarantee marketing exclusivity[168]. - The company may pursue Rare Pediatric Disease designation for QRX003, but there is no assurance of obtaining such designation or priority review vouchers[169]. Market Competition and Commercialization - The company faces intense competition from larger pharmaceutical companies with greater resources, which may hinder its ability to successfully develop and market its product candidates[171]. - Currently, there are no approved products for treating NS, but several competitors are in various stages of development, increasing market competition[172]. - The commercial success of the company's product candidates will depend on acceptance by the medical community, which is influenced by factors such as efficacy, safety, and pricing[178]. - The company currently lacks sales and marketing capabilities for pharmaceutical products, which may hinder revenue generation[179]. - Establishing a sales organization or forming strategic alliances is essential for future product commercialization, particularly in the U.S. and Europe[180]. - The company faces competition from well-funded companies with established marketing and sales operations, impacting its ability to generate sufficient product revenue[181]. - International commercialization poses risks, including differing regulatory requirements and potential economic instability in foreign markets[182]. - Coverage and adequate reimbursement for product candidates are uncertain, which could affect market acceptance and profitability[183]. - Legislative and regulatory changes in the healthcare system may negatively impact reimbursement for drug products[184]. Manufacturing and Supply Chain Risks - The company relies on third-party manufacturers for production, which introduces risks related to compliance and supply chain disruptions[189]. - Manufacturing issues could lead to increased costs and delays in regulatory approval, affecting commercialization timelines[194]. - The company intends to rely on third parties for clinical trials, which may impact the quality and timeliness of data collection and regulatory submissions[195]. - Performance failures by third-party logistics providers could delay clinical development and commercialization, resulting in potential revenue losses[199]. Intellectual Property Risks - The company faces risks related to intellectual property rights, which are crucial for competing effectively in the market[200]. - Patent applications may fail to issue or be challenged, potentially threatening the company's ability to commercialize future products[201]. - The lifespan of patents is limited, with one patent expiring in March 2024 and another set to expire in July 2025, exposing the company to competition from generic medications[203]. - The company relies on trade secret protection and confidentiality agreements, but there is no guarantee that these will be enforceable or adequately protect proprietary information[204]. - The company may face claims of intellectual property infringement, which could lead to substantial litigation expenses and distract management from business operations[207]. Management and Operational Risks - The company is dependent on key executives and may struggle to attract and retain qualified personnel due to industry competition[216]. - Future growth may require significant capital expenditures and could divert financial resources from other projects, impacting the company's ability to implement its business strategy[217]. - Employee misconduct poses risks, including noncompliance with regulatory standards, which could lead to significant penalties and harm the company's reputation[219]. - The company must comply with federal and state healthcare fraud and abuse laws, and failure to do so could result in criminal sanctions and diminished profits[220]. Regulatory and Legislative Risks - The company anticipates potential expansion of operations in the EU, including preclinical and clinical trials, subject to GDPR regulations[223]. - Legislative changes, such as the Inflation Reduction Act, may allow the federal government to negotiate drug prices, impacting revenue generation[230]. - The American Rescue Plan Act of 2021 eliminated the statutory cap on Medicaid Drug Rebate Program rebates, potentially increasing costs for pharmaceutical manufacturers[226]. - The ACA provisions may reduce drug product profitability through increased Medicaid rebates and mandatory discounts for Medicare beneficiaries[226]. - Increased scrutiny of drug pricing practices may lead to legislative changes that could affect the company's pricing strategies[229]. - Future healthcare reforms may hinder the company's ability to generate revenue and commercialize product candidates[232]. Liability and Risk Management - The company faces risks related to product liability claims, which could result in substantial costs and impact business reputation[234]. - Cybersecurity risks could lead to operational disruptions and potential legal claims, affecting the company's reputation and financial standing[237]. - The company may incur civil and criminal penalties for violations of healthcare regulations, impacting operations and financial results[224]. - The company plans to obtain product liability insurance, but coverage may not be sufficient to cover potential liabilities[236]. Market and Stock Risks - The company received a deficiency letter from Nasdaq regarding its ADSs not maintaining a minimum closing bid price of $1.00 for 31 consecutive business days[251]. - The company has until April 28, 2025, to regain compliance with Nasdaq's Minimum Bid Price Requirement, or it risks delisting[253]. - If delisted, the company may face additional regulatory burdens and a significant decrease in market liquidity for its ADSs[255]. - The market price for the company's ADSs is likely to be highly volatile, influenced by various factors including clinical trial approvals and regulatory actions[256]. - The company has not paid any cash dividends on its ordinary shares and does not anticipate paying any in the foreseeable future, which may limit investor benefits unless market prices appreciate[262]. - Substantial future sales of the company's ADSs could lead to a decline in their market price, potentially affecting existing shareholders negatively[260]. - Holders of ADSs may not receive the same distributions or dividends as those made to ordinary shareholders, which could lead to a material decline in the value of the ADSs[263]. - The company may face risks of securities class action litigation, particularly related to clinical trial outcomes and regulatory approvals, which could divert management's attention and resources[259]. - The depositary for the ADSs may withhold dividends or distributions due to legal or practical reasons, impacting the value received by ADS holders[263]. - The company may experience significant stock price volatility associated with clinical trials and product approvals, which is common in the medical and biotechnology sectors[259]. - Holders of ADSs must act through the depositary to exercise their rights, which may limit their ability to vote on shareholder matters[264]. - The depositary may close its transfer books at any time, potentially limiting the transferability of ADSs[265]. - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[335].

Financial Performance - Quoin Pharmaceuticals reported a net loss of approximately $2.3 million for Q4 2024, compared to a net loss of approximately $2.0 million for Q4 2023, and a total net loss of $9.0 million for the full year 2024, up from $8.7 million in 2023[12]. - Operating expenses for Q4 2024 were approximately $9.5 million, slightly higher than $9.4 million in Q4 2023[17]. - Total current assets increased to approximately $14.9 million as of December 31, 2024, compared to $11.3 million in 2023[16]. Cash and Funding - As of December 31, 2024, Quoin had approximately $14.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into Q2 2026[12]. - The company completed a $6.8 million public offering on December 20, 2024, enhancing its financial position for ongoing clinical development[9]. Clinical Development - Quoin's ongoing clinical studies for QRX003 have shown significant improvements in disease severity and skin healing for patients with Netherton Syndrome, with one patient experiencing transformational improvement after just two weeks[5]. - The FDA cleared a new whole-body clinical study for QRX003, which will evaluate its safety and efficacy on over 80% of the body surface area in Netherton Syndrome patients[10]. - Quoin filed U.S. and international patent applications for novel topical rapamycin formulations targeting rare dermatological diseases, expanding its product pipeline[4]. Awareness and Education - The company launched the 'NETHERTON NOW' awareness campaign to raise awareness about Netherton Syndrome, including a dedicated website for educational resources[6]. Shareholder Information - The weighted average number of ADSs outstanding increased to 4,688,723 for the year ended December 31, 2024, compared to 900,919 in 2023[17].